BELITE BIO, INC
BLTE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BLTE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLTE
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal degenerative diseases, with its lead product candidate tinlarebant in Phase 3 trials for Stargardt disease and geographic atrophy.
Key risk: Need for additional capital
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2025.
Tracking 3 clinical trials · 2 catalysts for BELITE BIO, INC.
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal degenerative diseases, with its lead product candidate tinlarebant in Phase 3 trials for Stargardt disease and geographic atrophy.
- Lead product candidate tinlarebant is in Phase 3 clinical development for Stargardt disease and geographic atrophy [sec · filed 2026-03-31].
- As of December 31, 2025, the company reported cash and equivalents of $352.9 million, net income of -$77.6 million, and shareholders' equity of $145.8 million [sec].
- The company has recorded net cash outflow from operating activities since inception and expects to need additional financing to fund operations and complete development [sec · filed 2026-03-31].
- Belite Bio also has a preclinical candidate, LBS-009, in early development [sec · filed 2026-03-31].
- The company faces risks related to its ability to obtain regulatory approval and commercialize its product candidates, as well as its dependence on future funding [sec · filed 2026-03-31].
What works
- Belite Bio has a lead candidate, tinlarebant, that is already in Phase 3 trials, indicating advanced clinical development [sec · filed 2026-03-31].
- The company reported a substantial cash position of $352.9 million as of December 31, 2025, which may support near-term operations [sec].
- Tinlarebant targets large-market retinal diseases (Stargardt disease and geographic atrophy), which have significant unmet medical need [sec · filed 2026-03-31].
What to weigh
- The company has a history of net losses and negative cash flows from operations, with a net loss of $77.6 million in 2025 [sec].
- Belite Bio states that its existing cash will not be sufficient to meet all short-term obligations or long-term plans, including completing clinical trials or commercialization [sec · filed 2026-03-31].
- All product candidates (tinlarebant and LBS-009) are in clinical or preclinical stages, with no approved products or revenue from product sales [sec · filed 2026-03-31].
- The company will need additional financing, which may not be available on acceptable terms, and failure to raise capital could force delays or reductions in development programs [sec · filed 2026-03-31].
From the filings
Quoted directly from source documents.
Lead candidate tinlarebant is in Phase 3 trials
“continue to develop and conduct clinical trials with respect to our lead product candidate, tinlarebant”
SEC filings · March 31, 2026
Need for additional financing
“We will need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our product candidates.”
SEC filings · March 31, 2026
All product candidates are in clinical or preclinical development
“All of our product candidates (i.e. tinlarebant and LBS-009) are in clinical or preclinical development.”
SEC filings · March 31, 2026
Catalyst timeline
- 2027-08-31 · Phase3_Topline · tinlarebant — Phase 3 Topline: PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore — Topline results from the Phase 3 trial of tinlarebant will be a key efficacy and safety readout for the lead candidate.
- 2028-02-01 · Phase3_Topline — Phase 3 Topline: A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerabi — Topline results from a Phase 1b study will provide pharmacokinetic and safety data for tinlarebant.
Risks & what to watch (4)›
Key risks
- Need for additional capital — Existing cash is insufficient to meet all obligations; failure to raise funds may delay or halt development [sec · filed 2026-03-31].
- No approved products or revenue — All candidates are in clinical/preclinical stages; no product sales or regulatory approvals yet [sec · filed 2026-03-31].
- Clinical development risks — Tinlarebant and LBS-009 may fail to show efficacy or safety in trials, leading to delays or failure [sec · filed 2026-03-31].
- Dependence on single lead candidate — Company's prospects rely heavily on tinlarebant; setbacks could materially harm the business [sec · filed 2026-03-31].
What to watch
- Phase 3 topline data for tinlarebant expected around August 31, 2027 [upcoming catalysts].
- Additional financing events or partnership announcements to extend cash runway [sec · filed 2026-03-31].
- Regulatory interactions and potential filing for tinlarebant in Stargardt disease or geographic atrophy [sec · filed 2026-03-31].
- Progress of preclinical candidate LBS-009 into clinical trials [sec · filed 2026-03-31].
Sources: SEC filings · Generated August 17, 2026 · How we verify sources →
Run BELITE BIO, INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BELITE BIO, INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
32.1 months
D/E 0.01 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~366d
0 buys · 129 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
71
Total value held
$549.2M
| Holder | Shares | Value |
|---|---|---|
| rtw investments, lp | 715,332 | $114.1M |
| millennium management llc | 570,088 | $90.9M |
| eventide asset management, llc | 357,650 | $57.0M |
| deerfield management company, l.p. | 304,013 | $48.5M |
| perceptive advisors llc | 303,958 | $48.5M |
| morgan stanley | 201,409 | $32.1M |
| patient square capital lp | 116,684 | $18.6M |
| goldman sachs group inc | 105,509 | $16.8M |
| mpm bioimpact llc | 88,045 | $14.0M |
| affinity asset advisors, llc | 65,000 | $10.4M |
Showing top 10 of 71 institutional holders of BELITE BIO, INC. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 6.0%
- Days to cover
- 8.8
- Shares short
- 1,233,097
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BLTE short interestFrequently asked questions
What is the AI investment thesis for BELITE BIO, INC?
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal degenerative diseases, with its lead product candidate tinlarebant in Phase 3 trials for Stargardt disease and geographic atrophy.
What is BELITE BIO, INC's next catalyst?
BELITE BIO, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore " — expected August 31, 2027.
Who is the CEO of BELITE BIO, INC?
Dr. Yu-Hsin Lin M.B.A., Ph.D. is the chief executive officer of BELITE BIO, INC (BLTE).
Where is BELITE BIO, INC headquartered?
BELITE BIO, INC (BLTE) is headquartered in San Diego, CA, United States.
What therapeutic areas does BELITE BIO, INC focus on?
BELITE BIO, INC develops therapies across Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.